Rumble to Present at the Q3 Virtual Investor Summit Microcap Event
LONGBOAT KEY, FL / ACCESSWIRE / August 19, 2024 / Rumble Inc. (NASDAQ:RUM) (the "Company"), the video-sharing platform and cloud services provider, today announced that members of the Company's management will present virtually at the Investor Summit Microcap Event on Tuesday, August 20th.
Event: Q3 Investor Summit
Date: August 20th, 2024
Presentation Time: 4:00pm ET
Location: Webcast Link
Live Q&A
Complimentary to Qualified Investors. Please REGISTER HERE.
ABOUT RUMBLE
Rumble is a high-growth video platform and cloud services provider that is creating an independent infrastructure. Rumble's mission is to restore the internet to its roots by making it free and open once again. For more information, visit: corp.rumble.com.
About the Investor Summit
The Investor Summit is an exclusive, independent conference dedicated to connecting small cap and microcap companies with qualified investors. Founded in 2015.
For investor inquiries, please contact:
Shannon Devine
MZ Group, MZ North America
203-741-8811
investors@rumble.com
Investor Summit Contact:
Fred Rockwell
fred@investorsummitgroup.com
Investor Summit Group
SOURCE: Rumble Inc
View the original press release on accesswire.com
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks